James M. Daly - 01 Oct 2026 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Reporting relationship: Director
Issuer ticker: HALO
Reported as of: 01 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Oct 2026, 16:43:41 UTC
Prior SEC filing: 02 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ James R. Oehler, Attorney-in-Fact

Filing notes and source

Key filing fact

James M. Daly filed Form 4 for HALOZYME THERAPEUTICS, INC. (HALO) on 02 Oct 2026.

Key facts

This page summarizes James M. Daly's Form 4 filing for HALOZYME THERAPEUTICS, INC. (HALO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Oct 2026, 16:43.

Change

Previous filing in this sequence was filed on 02 Oct 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001560782 Primary reporting owner

Daly James M

Relationship: Director
Address: C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO
Signature: /s/ James R. Oehler, Attorney-in-Fact
Signature date: 02 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HALO transaction

Restricted Stock Units

Award

Transaction value
Shares: +1,169
Change %
Price: $0.000000^*
Shares after: 1,169
Date: 01 Oct 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HALO transaction Derivative

Option to Purchase Common Stock

Award

Transaction value
Shares: +1,775
Change %
Price: $0.000000^*
Shares after: 1,775
Date: 01 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,775
Exercise price: $106.94
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders.

Footnote F2

Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders.